 Despite the progress made with the recent clinical use of the anticancer compound cabazitaxel the efficacy in patients remains unsatisfactory largely due to the high

@highlight PUFAylation of anticancer cabazitaxel drug facilitated the incorporation of the drug into liposomal formulation.
@highlight The liposomal prodrug termed
@highlight  was established for the drug optimization.
@highlight Lipoprodrug scaffold showed sustained drug release profiles
@highlight and improved pharmacokinetics
@highlight Lipoprodrug potentiated the efficacy of cabazitaxel in multiple mice models including a patient derived xenograft model.
@highlight Lipoprodrug remarkably alleviated the toxicity with a high safety margin relative to cabazitaxel in animals.
